HCW Biologics Inc HCWB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.46
- Day Range
- $1.35–1.41
- 52-Week Range
- $0.91–2.32
- Bid/Ask
- $1.35 / $1.39
- Market Cap
- $52.95 Mil
- Volume/Avg
- 2,444 / 16,324
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 45
- Website
- https://www.hcwbiologics.com
Comparables
Valuation
|
Metric
|
HCWB
|
TGTX
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.99 | — |
Price/Book Value | 3.75 | 13.44 | 1.50 |
Price/Sales | 17.70 | 9.06 | 441.50 |
Price/Cash Flow | — | 39.74 | — |
Price/Earnings
HCWB
TGTX
PLRX
Financial Strength
|
Metric
|
HCWB
|
TGTX
|
PLRX
|
|---|---|---|---|
Quick Ratio | 0.59 | 5.00 | 17.43 |
Current Ratio | 0.73 | 5.92 | 17.72 |
Interest Coverage | −87.31 | 2.04 | −145.34 |
Quick Ratio
HCWB
TGTX
PLRX
Profitability
|
Metric
|
HCWB
|
TGTX
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −62.53% | 19.44% | −22.68% |
Return on Equity (Normalized) | −89.20% | 54.76% | −24.50% |
Return on Invested Capital (Normalized) | −71.45% | 35.76% | −28.46% |
Return on Assets
HCWB
TGTX
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zwkjmwmwn | Ncmv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jfghjrmj | Vrgtdk | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yrpmyyhgn | Wbqgpwx | $97.8 Bil | |
MRNA
| Moderna Inc | Dlxdgxmst | Cfnpj | $41.3 Bil | |
ARGX
| argenx SE ADR | Wgzfhbylc | Ksbfq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Bfhlchcf | Mhxf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lzwsgcwk | Ynyfy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fqjsyrxg | Gzjfqfp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nyffvhjdws | Mklnq | $12.5 Bil | |
INCY
| Incyte Corp | Gvbqfsxt | Qqjtgfm | $11.6 Bil |